erythema nodosum leprosum (enl)

Number of resources: 34

Lepromatous leprosy in erythema nodosum leprosum reaction mimicking Sweet’s syndrome

 
Heng YK, Chiam YT, Giam YC, Chong WS. Lepromatous leprosy in erythema nodosum leprosum reaction mimicking Sweet’s syndrome. Int Jrn Dermat. 2011;50(9):1124-5.

Co-existent acquired perforating collagenosis and lepromatous leprosy with erythema nodosum leprosum: Response to treatment.

 
Gupta L, Singal A, Pandhi D, Sharma S. Co-existent acquired perforating collagenosis and lepromatous leprosy with erythema nodosum leprosum: Response to treatment. Indian J Dermatol Venereol Leprol. 2011;77(4):520-2.

A Patient with Erythema Nodosus Leprosum and Chagas Cardiopathy: Challenges in Patient Management and Review of the Literature.

 
Trindade MÂ, Carvalho NB, Belfort EC, Pagliari C, Gakiya E, Sakai-Valente NY, et al. A Patient with Erythema Nodosus Leprosum and Chagas Cardiopathy: Challenges in Patient Management and Review of the Literature. The American journal of tropical medicine and hygiene. 2011;84(6):973-7.

Severe vasculonecrotic erythema nodosum leprosum following thalidomide withdrawal without tapering doses: do we have something unusual?

 
Mahajan VK, Chauhan PS, Sharma NL, Sharma AL, Mehta KI. Severe vasculonecrotic erythema nodosum leprosum following thalidomide withdrawal without tapering doses: do we have something unusual? Braz J Infect Dis. 2011;15(1):90-1.

In Vitro Thalidomide Does Not Interfere With the Activation of Complement by M. leprae.

 
Shannon EJ, Sandoval FG, Morales MJ. In Vitro Thalidomide Does Not Interfere With the Activation of Complement by M. leprae. J Drugs Dermatol. 2011;10(3):274-8.

Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept.

 
Ramien ML, Wong A, Keystone JS. Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. Clin Infect Dis. 2011;52(5):e133-5.

[Thalidomide--coverage by health insurance when used for treatment of ENL].

 
Ishii N. [Thalidomide--coverage by health insurance when used for treatment of ENL]. Nihon Hansenbyo Gakkai Zasshi. 2010;79(3):275-9.

Severe form of type 2 reaction in patients of Hansen's disease after withdrawal of thalidomide: case reports.

 
Rattan R, Shanker V, Tegta GR, Verma GK. Severe form of type 2 reaction in patients of Hansen's disease after withdrawal of thalidomide: case reports. Indian J Lepr. 2009;81(4):199-203.

[Persistent type 2 lepra reaction (erythema nodosum) and clofazimine-induced lethal enteropathy]

 
Rodríguez G, Pinto R, López F, Gómez Y. [Persistent type 2 lepra reaction (erythema nodosum) and clofazimine-induced lethal enteropathy]. Biomedica. 2009;29(1):18-24.

Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.

 
Feuth M, Brandsma WJ, Faber WR, Bhattarai B, Feuth T, Anderson AM. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide. Lepr Rev. 2008;79(3):254-69.

Ref: Role of azathioprine in preventing recurrence of ENL in a patient--article by K K Verma et al. Lepr Rev (2006) 77: 225-229.

 
Sunkad M. Ref: Role of azathioprine in preventing recurrence of ENL in a patient--article by K K Verma et al. Lepr Rev (2006) 77: 225-229. Lepr Rev. 2007;78(2):170.

Serologic recognition of low molecular weight mycobacterial protein fractions in lepromatous patients with type II reactions (ENL).

 
Rada EM, Zambrano EA, Aranzazu N, Convit J. Serologic recognition of low molecular weight mycobacterial protein fractions in lepromatous patients with type II reactions (ENL). Int J Lepr Other Mycobact Dis. 2005;73(3):222-5.

Methotrexate in resistant ENL.

 
Kar BR, Babu R. Methotrexate in resistant ENL. Int J Lepr Other Mycobact Dis. 2004;72(4):480-2.

Chronic recurrent ENL, steroid dependent: long-term treatment with high dose clofazimine.

 
Schreuder PA, Naafs B. Chronic recurrent ENL, steroid dependent: long-term treatment with high dose clofazimine. Lepr Rev. 2003;74(4):386-9.

Pulsed corticosteroid therapy in patients with chronic recurrent ENL: a pilot study.

 
Girdhar A, Chakma JK, Girdhar BK. Pulsed corticosteroid therapy in patients with chronic recurrent ENL: a pilot study. Indian J Lepr. 2002;74(3):233-6.

ENL reactions in the multibacillary cases of the AMFES cohort in central Ethiopia: incidence and risk factors.

 
Saunderson P, Gebre S, Byass P. ENL reactions in the multibacillary cases of the AMFES cohort in central Ethiopia: incidence and risk factors. Lepr Rev. 2000;71(3):318-24.

Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL).

 
Moraes MO, Sarno EN, Almeida AS, Saraiva BC, Nery JA, Martins RC, et al. Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand J Immunol. 1999;50(5):541-9.
Syndicate content